492 related articles for article (PubMed ID: 38245798)
1. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
Hu Y; Dong Z; Liu K
J Exp Clin Cancer Res; 2024 Jan; 43(1):23. PubMed ID: 38245798
[TBL] [Abstract][Full Text] [Related]
2. Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma.
Zhou J; Chng WJ
Cells; 2022 Mar; 11(6):. PubMed ID: 35326392
[TBL] [Abstract][Full Text] [Related]
3. Targeting STAT3 in Cancer Immunotherapy.
Zou S; Tong Q; Liu B; Huang W; Tian Y; Fu X
Mol Cancer; 2020 Sep; 19(1):145. PubMed ID: 32972405
[TBL] [Abstract][Full Text] [Related]
4. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
Kim BH; Yi EH; Ye SK
Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
6. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
[TBL] [Abstract][Full Text] [Related]
7. Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment.
Liu Q; Yu S; Li A; Xu H; Han X; Wu K
Tumour Biol; 2017 Jun; 39(6):1010428317712445. PubMed ID: 28639898
[TBL] [Abstract][Full Text] [Related]
8. Signal transducer and activator of transcription 3 downregulation in J774A.1 cell line as a model of M2 macrophages in tumor microenvironment.
Seyedi Z; Hashemzadeh MR; Colagar AH; Jaafari MR
J Cancer Res Ther; 2018; 14(5):1121-1125. PubMed ID: 30197360
[TBL] [Abstract][Full Text] [Related]
9. Highlighted STAT3 as a potential drug target for cancer therapy.
Lee H; Jeong AJ; Ye SK
BMB Rep; 2019 Jul; 52(7):415-423. PubMed ID: 31186087
[TBL] [Abstract][Full Text] [Related]
10. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
[TBL] [Abstract][Full Text] [Related]
11. Role of STAT3 in cancer metastasis and translational advances.
Kamran MZ; Patil P; Gude RP
Biomed Res Int; 2013; 2013():421821. PubMed ID: 24199193
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
Kitamura H; Ohno Y; Toyoshima Y; Ohtake J; Homma S; Kawamura H; Takahashi N; Taketomi A
Cancer Sci; 2017 Oct; 108(10):1947-1952. PubMed ID: 28749573
[TBL] [Abstract][Full Text] [Related]
13. Identification of serum and glucocorticoid-regulated kinase 1 as a regulator of signal transducer and activator of transcription 3 signaling.
Araki T; Watanabe Y; Okada Y; Murakami H; Ogo N; Asai A
Exp Cell Res; 2022 Apr; 413(2):113079. PubMed ID: 35202674
[TBL] [Abstract][Full Text] [Related]
14. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Beebe JD; Liu JY; Zhang JT
Pharmacol Ther; 2018 Nov; 191():74-91. PubMed ID: 29933035
[TBL] [Abstract][Full Text] [Related]
15. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
16. Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature.
Mohan CD; Rangappa S; Preetham HD; Chandra Nayaka S; Gupta VK; Basappa S; Sethi G; Rangappa KS
Semin Cancer Biol; 2022 May; 80():157-182. PubMed ID: 32325172
[TBL] [Abstract][Full Text] [Related]
17. New insights into the roles of ncRNA in the STAT3 pathway.
Zhang J; Zhang A; Wang Y; Liu N; You Y; Kang C; Pu P
Future Oncol; 2012 Jun; 8(6):723-30. PubMed ID: 22764770
[TBL] [Abstract][Full Text] [Related]
18. Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: New insight to proliferation and metastasis.
Ashrafizadeh M; Gholami MH; Mirzaei S; Zabolian A; Haddadi A; Farahani MV; Kashani SH; Hushmandi K; Najafi M; Zarrabi A; Ahn KS; Khan H
Life Sci; 2021 Apr; 270():119006. PubMed ID: 33421521
[TBL] [Abstract][Full Text] [Related]
19. Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.
Huang TT; Su JC; Liu CY; Shiau CW; Chen KF
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594363
[TBL] [Abstract][Full Text] [Related]
20. Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors.
Lee M; Hirpara JL; Eu JQ; Sethi G; Wang L; Goh BC; Wong AL
Redox Biol; 2019 Jul; 25():101073. PubMed ID: 30594485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
